Square Pharmaceuticals PLC. announcements
313 Dhaka Stock Exchange announcements for Square Pharmaceuticals PLC. (SQURPHARMA) since 2007: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2017 (19).
- Credit Rating Result
Credit Rating Information and Services Limited (CRISL) has rated the Company as "AAA" in the long term and "ST-1" in the short term along with a stable outlook in consideration of its audited financials up to June 30, 2017, unaudited financials up to September 30, 2017 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
- Stock Dividend Disbursement
The Company has informed that it has credited the bonus shares for the year ended on June 30, 2017 to the respective shareholders' BO Accounts on December 11, 2017.
- Q1 Financials
(Q1 Un-audited): Consolidated EPS was Tk. 4.39 for July-September, 2017 as against Tk. 3.53 for July-September, 2016; Consolidated NOCFPS was Tk. 5.41 for July-September, 2017 as against Tk. 5.16 for July-September, 2016. Consolidated NAV per share was Tk. 76.22 as on September 30, 2017 and Tk. 71.47 as on June 30, 2017.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 14, 2017 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2017.
- Resumption after record date
Trading of the shares of the Company will resume on 09.11.2017 after record date.
- Suspension for Record Date
Trading of the shares of the Company will remain suspended on record date i.e., 08.11.2017.
- Spot News
Trading of the shares of the Company will be allowed only in the Spot Market and Block transactions will also be settled as per Spot settlement cycle with cum benefits from 06.11.2017 to 07.11.2017. Trading of the shares of the Company will remain suspended on record date i.e., 08.11.2017.
- Approval of Merger by the Board
The Company has informed that the Board of Directors has approved the following matters subject to the approval of the shareholders in the General Meeting and sanction by the Hon'ble High Court Division of the Supreme Court of Bangladesh: 1. Merger of Square Formulations Ltd. with the Square Pharmaceuticals Ltd., 2. Merger of Square Herbal & Nutraceuticals Ltd. with the Square Pharmaceuticals Ltd.
- Dividend Declaration & BMRE, Capital Machineries, Land for expansion
The Board of Directors has recommended 35% cash and 7.5% stock dividend for the year ended on June 30, 2017. The Board has also approved Tk. 202.00 crore for BMRE, Capital Machineries and Lands for future expansion. Date of AGM: 04.12.2017, Time: 10:00 AM, Venue: Samson H Chowdhury Centre Dhaka Club Ltd., Ramna, Dhaka. Record Date: 08.11.2017. (cont.) (Continuation news of SQURPHARMA): The Company has also reported Consolidated EPS of Tk. 15.51, Consolidated NAV per share of Tk. 71.47 and Consolidated NOCFPS of Tk. 13.92 for the year ended on June 30, 2017 as against Tk. 13.41, Tk. 59.12 and Tk. 14.02 respectively for the same period of the previous year. (end)
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (17.10.2017) following its corporate declaration.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 16, 2017 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2017.
- Transmission of shares of a late Sponsor among his successors
The Company has informed that a total of 2,62,47,368 shares of late Sponsor Dr. Kazi Harunar Rashid has been transmitted to his legal heirs according to the succession certificate issued by the Honorable Court: i) 1,31,23,684 shares to Mr. Kazi Iqbal Harun (son, Director of the Company), ii) 65,61,842 shares to Mrs. Nilufar Ferdous (daughter) and iii) 65,61,842 shares to Mrs. Nargis Ferdous (daughter).
- Agreements for manufacturing products to meet increased demand
The Company has informed that the Board of Directors has approved agreements with M/s. NAAFCO Pharma Ltd. and M/s. Sharif Pharmaceuticals Ltd., Dhaka, Bangladesh for contract manufacturing of some products on behalf of Square Pharmaceuticals Limited to meet increased demand of existing products and to introduce new products.
- Q3 Financials
(Q3 Un-audited): Consolidated EPS was Tk. 4.27 for January-March 2017 as against Tk. 3.64 for January-March 2016; Consolidated EPS was Tk. 11.39 for July 2016-March 2017 as against Tk. 9.74 for July'15-March'16. Consolidated NOCFPS was Tk. 12.35 for July 2016-March 2017 as against Tk. 12.08 for July 2015-March 2016. Consolidated NAV per share was Tk. 67.51 as of March 31, 2017 and Tk. 59.13 as of June 30, 2016.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 30, 2017 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2017.
- Q2 Financials
(Q2 Un-audited): Consolidated EPS was Tk. 3.58 for October-December, 2016 as against Tk. 3.21 for October-December, 2015; Consolidated EPS was Tk. 7.11 for July-December, 2016 as against Tk. 6.10 for July-December, 2015. Consolidated NOCFPS was Tk. 8.54 for July-December, 2016 as against Tk. 8.93 for July-December, 2015. Consolidated NAV per share was Tk. 63.00 as of December 31, 2016 and Tk. 59.13 as of June 30, 2016.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 29, 2017 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2016.
- Dividend Disbursement
The Company has informed that it has disbursed the cash dividend warrants for the 15 months period ended on June 30, 2016 to the respective shareholders' mailing address.
- Decision to establish a Subsidiary Company in Kenya
The Company has informed that the Board of Directors has decided to establish a pharmaceuticals manufacturing subsidiary company in Nairobi, Kenya. The Initial estimated total project cost will be US$ 20.00 million. US$ 8.00 million of it will be financed by equity investment by the company for which Bangladesh Bank has given permission and the balance would be invested from loan. It is expected that the project would be completed by June 2019.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.